Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients

The research team has planned to conduct three interim analyses for safety and one final report. The interim analyses will be conducted as follows:

• First interim analysis: After the completion of the last volunteer of the group with body weight >30 kg receiving ivermectin 400 μg/kg every 24 hours for a total of three times (i.e. the sixth volunteer).
• Second interim analysis: After the completion of the last volunteer of the group with body weight >30 kg receiving ivermectin 600 μg/kg every 24 hours for a total of three times (i.e. the twelfth volunteer).
• Third interim analysis: After the completion of the last volunteer of the group with body weight 15 to 30 kg receiving ivermectin 400 μg/kg every 24 hours for a total of three times (i.e. the twelfth volunteer).

The results of each interim analyses will be submitted to DSMB to determine whether the study is safe to be conducted in the next group of volunteers. Additionally, the results of interim analyses and the safety assessments from DSMB will be submitted to all ECs

Inclusion criteria

• Aged between 1-15 years 0 day
• Weight is equal or greater than 15 kg
• History or presence of acute fever within the last 72 hours diagnosed as acute dengue virus infection
• Patients who are expected to be able to start the study drug within 72 hours of fever
• Written informed consent to enroll in the study is obtained from parents or legal representatives and/or patients.
• The test for dengue nonstructural protein 1 is positive, or PCR screening for viral genome is positive
• Female patients with history of menarche need to have a negative result for urine pregnancy test, except during a menstrual period.

Exclusion criteria

• Has significant underlying disease(s) that can affect the study outcome or the study participation may be harmful to patients with those underlying diseases including but not limited to:

• Kidney disease
• Thalassemia
• congenital heart disease
• epilepsy
• cerebral palsy Other underlying diseases may result in exclusion depending on the judgement of investigator.
• Having developed or showed the following laboratory values, warning signs or signs of severe dengue including:

• AST and/or ALT levels > 500 IU/L
• Platelets count < 50,000 cells/mm3
• Abdominal pain or tenderness
• Persistent vomiting
• Clinical fluid accumulation such as pleural effusion, ascites
• Mucosal bleeding
• Lethargy/restlessness
• Liver enlargement >2 cm
• Increase in Hct concurrent with rapid decrease in platelet count
• Severe plasma leakage such as dengue shock syndrome, fluid accumulation with respiratory distress
• Severe bleeding as evaluated by clinician
• Severe organ involvement including but not limited to acute liver failure, altered level of consciousness (e.g. encephalopathy, encephalitis), seizure or other CNS unusual manifestation, acute renal failure, cardiomyopathy and other unusual manifestation
• History of ivermectin allergy or receiving medications that increase gamma-aminobutyric acid (GABA) potentiating activity such as barbiturates, benzodiazepines, sodium oxybate, valproic acid, or receiving medications that prevent p-glycoprotein transport system such as amiodarone, carvedilol, clarithromycin, cyclosporine, erythromycin, itraconazole, ketoconazole, quinidine, ritonavir, tamoxifen, verapamil, amprenavir, clotrimazole, phenothiazines, rifampin, St. John's Wort etc.
• Currently receiving immunosuppressive agents such as steroid (except topical steroid), chemotherapeutic agents or have discontinued these medications for less than a month
• Having a history of receiving ivermectin within one month
• Inability to ingest medications in a form of tablets as informed by patients and their parents or legal representatives